TABLE 1.
Antimicrobial susceptibility profiles of S. Typhi isolates
| Sample | Collection date (mo-yr) | Specimen type | MIC (mg/liter) and susceptibility ofa
: |
Genotypic resistance | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZM | AMC | AMP | FOX | CRO | CHL | CIP | GEN | MEM | STR | TET | SXT | ||||
| PHL5950 | Jul-18 | Blood | 4 (S) | 16/8 (I) | >32 (R) | 4 (S) | >64 (R) | >32 (R) | 2 (R) | 0.5 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL4653 | Sep-18 | Stool | 4 (S) | 8/4 (S) | >32 (R) | 8 (S) | >64 (R) | >32 (R) | 4 (R) | ≤0.25 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL3183 | Jan-19 | Blood | 4 (S) | 8/4 (S) | >32 (R) | 4 (S) | >64 (R) | >32 (R) | 2 (R) | 0.5 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL9922 | Dec-18 | Blood | 4 (S) | 16/8 (S) | >32 (R) | 8 (S) | >64 (R) | >32 (R) | 2 (R) | ≤0.25 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7, tet(A) |
| PHL3127 | Jan-19 | Blood | 4 (S) | 8/4 (S) | >32 (R) | 4 (S) | >64 (R) | >32 (R) | 2 (R) | 0.5 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL4981 | Apr-19 | Blood | 4 (S) | 8/4 (S) | >32 (R) | 4 (S) | >64 (R) | >32 (R) | 2 (R) | 0.5 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL4949 | Sep-18 | Blood | 4 (S) | 8/4 (S) | >32 (R) | 4 (S) | >64 (R) | >32 (R) | 2 (R) | 0.5 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL8802 | Apr-19 | Blood | 4 (S) | 16/8 (I) | >32(R) | 8 (S) | >64 (R) | >32 (R) | 2 (R) | 0.5 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL3828 | May-19 | Blood | 4 (S) | 16/8 (I) | >32 (R) | 8 (S) | >64 (R) | >32 (R) | 2 (R) | ≤0.25 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
| PHL4989 | Apr-19 | Blood | 4 (S) | 16/8 (I) | >32 (R) | 8 (S) | >64 (R) | >32 (R) | 2 (R) | ≤0.25 (S) | ≤0.06 (S) | >64 (R) | ≤4 (S) | >4/76 (R) | aph(6)-Id, aac(6′)-Iaa, aph(3″)-Ib, blaTEM-1B, blaCTX-M-15, qnrS1, S83F, catA1, sul1, sul2, dfrA7 |
a
CLSI document M100-S29 clinical interpretative breakpoints criteria were used to determine susceptibility profile (8). AZM, azithromycin; AMC, amoxicillin-clavulanate; AMP, ampicillin; FOX, cefoxitin; CRO, ceftriaxone; CHL, chloramphenicol; CIP, ciprofloxacin; GEN, gentamicin; MEM, meropenem; STR, streptomycin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; S, susceptible; I, intermediate; R, resistant.